STUDY IN WHICH THERAPY IS EITHER SWITCHED TO NIVOLUMAB AFTER 3 MONTHS OF TREATMENT OR THERAPY IS CONTINUED WITH A TYROSINE KINASE INHIBITOR IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCC) AND DISEASE CONTROL: